Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Agios Pharma (AGIO) data from Phase 1 trial of AG-120 underwhelms investors

Source Link:: http://seekingalpha.com/news/2912526-phase-1-data-agminus-120-fails-excite-investors-agios-pharma-12-percent

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AGIO

100%

CELG

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein, and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation.

http://www.agios.com...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 09, 2015

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Data, Ag-120, Idh1 Inhibitor, Glioma, Sarcoma, Liver Tumor